| [1] | CUDDAPAH V A, ROBEL S, WATKINS S, et al. A neurocentric perspective on glioma invasion[J]. Nat Rev Neurosci, 2014, 15(7):455-465. doi: 10.1038/nrn3765 |
| [2] | GRILL J, OWENS C. Central nervous system tumors[J]. Handb Clin Neurol, 2013, 112:931-958. |
| [3] | PRELAJ A, REBUZZI S E, CAFFARENA G, et al. Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: case report and review of the literature[J]. Oncol Lett, 2018, 15(5):6641-6647. |
| [4] | CHOWDHRY S, ZANCA C, RAJKUMAR U, et al. NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling[J]. Nature, 2019, 569(7757):570-575. doi: 10.1038/s41586-019-1150-2 |
| [5] | SCHOLZ N, KURIAN K M, SIEBZEHNRUBL F A, et al. Targeting the ubiquitin system in glioblastoma[J]. Front Oncol, 2020, 10:574011. doi: 10.3389/fonc.2020.574011 |
| [6] | GUJAR A D, LE S, MAO D D, et al. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma[J]. Proc Natl Acad Sci U S A, 2016, 113(51):E8247-E8256. |
| [7] | ZENG S X, HUANGW H, ZHENG X L, et al. Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges[J]. Eur J Med Chem, 2021, 210:112981. doi: 10.1016/j.ejmech.2020.112981 |
| [8] | BRICELJ A, STEINEBACH C, KUCHTA R, et al. E3 ligase ligands in successful PROTACs: an overview of syntheses and linker attachment points[J]. Front Chem, 2021, 9:707317. doi: 10.3389/fchem.2021.707317 |
| [9] | SILVA N I O, SALVADOR E A, FRANCOI R, et al. Bovine serum albumin nanoparticles induce histopathological changes and inflammatory cell recruitment in the skin of treated mice[J]. Biomed Pharmacother, 2018, 107:1311-1317. doi: 10.1016/j.biopha.2018.08.106 |
| [10] | HOANG B, ERNSTING M J, ROY A, et al. Docetaxel-carboxymethylcellulose nanoparticles target cells via a SPARC and albumin dependent mechanism[J]. Biomaterials, 2015, 59:66-76. doi: 10.1016/j.biomaterials.2015.04.032 |
| [11] | MOCAN L, MATEA C, TABARAN F A, et al. Photothermal treatment of liver cancer with albumin-conjugated gold nanoparticles initiates Golgi Apparatus-ER dysfunction and caspase-3 apoptotic pathway activation by selective targeting of Gp60 receptor[J]. Int J Nanomedicine, 2015, 10:5435-5445. |
| [12] | LIU Y C, HAN Y, FANG T, et al. Turning weakness into strength: albumin nanoparticle-redirected amphotericin B biodistribution for reducing nephrotoxicity and enhancing antifungal activity[J]. J Control Release, 2020, 324:657-668. doi: 10.1016/j.jconrel.2020.05.026 |
| [13] | GALLI U, COLOMBO G, TRAVELLI C, et al. Recent advances in NAMPT inhibitors: a novel immunotherapic strategy[J]. Front Pharmacol, 2020, 11:656. doi: 10.3389/fphar.2020.00656 |
| [14] | MENG R, ZHU H M, WANG Z W, et al. Preparation of drug-loaded albumin nanoparticles and its application in cancer therapy[J]. J Nanomater, 2022, 2022:1-12. |